IL95912A - שיטה להארכת חיי מדף של תאי דם - Google Patents
שיטה להארכת חיי מדף של תאי דםInfo
- Publication number
- IL95912A IL95912A IL9591290A IL9591290A IL95912A IL 95912 A IL95912 A IL 95912A IL 9591290 A IL9591290 A IL 9591290A IL 9591290 A IL9591290 A IL 9591290A IL 95912 A IL95912 A IL 95912A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- solution
- intracellular
- biologically compatible
- storage
- Prior art date
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims abstract description 216
- 239000000243 solution Substances 0.000 claims abstract description 86
- 230000003834 intracellular effect Effects 0.000 claims abstract description 67
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 47
- 238000005406 washing Methods 0.000 claims abstract description 35
- 239000008366 buffered solution Substances 0.000 claims abstract description 28
- 150000001450 anions Chemical class 0.000 claims abstract description 15
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 15
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 15
- 239000003792 electrolyte Substances 0.000 claims abstract description 8
- 230000003247 decreasing effect Effects 0.000 claims abstract description 7
- 238000007865 diluting Methods 0.000 claims abstract description 6
- 238000005534 hematocrit Methods 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 229930024421 Adenine Natural products 0.000 claims description 17
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 17
- 229960000643 adenine Drugs 0.000 claims description 17
- 239000012536 storage buffer Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 3
- 239000013024 dilution buffer Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 abstract description 20
- 230000001965 increasing effect Effects 0.000 abstract description 9
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 48
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 48
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 230000000877 morphologic effect Effects 0.000 description 24
- 206010018910 Haemolysis Diseases 0.000 description 23
- 230000008588 hemolysis Effects 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 21
- 229910019142 PO4 Inorganic materials 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 239000010452 phosphate Substances 0.000 description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 14
- 238000012423 maintenance Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 230000003139 buffering effect Effects 0.000 description 10
- 239000001509 sodium citrate Substances 0.000 description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000034659 glycolysis Effects 0.000 description 8
- 230000002035 prolonged effect Effects 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 102100024294 Mediator of RNA polymerase II transcription subunit 8 Human genes 0.000 description 5
- 101710161847 Mediator of RNA polymerase II transcription subunit 8 Proteins 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003716 rejuvenation Effects 0.000 description 5
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 4
- 239000006173 Good's buffer Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 4
- 239000000176 sodium gluconate Substances 0.000 description 4
- 235000012207 sodium gluconate Nutrition 0.000 description 4
- 229940005574 sodium gluconate Drugs 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000004254 Ammonium phosphate Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 229940010556 ammonium phosphate Drugs 0.000 description 3
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 3
- 235000019289 ammonium phosphates Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000037041 intracellular level Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960002901 sodium glycerophosphate Drugs 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000724832 Non-A, non-B hepatitis virus Species 0.000 description 1
- FGKOLPBZNQAHRP-UHFFFAOYSA-M P(=O)(=O)OC(C(=O)[O-])CO.[Na+] Chemical compound P(=O)(=O)OC(C(=O)[O-])CO.[Na+] FGKOLPBZNQAHRP-UHFFFAOYSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004555 blood preservation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- -1 chloride Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940116349 dibasic ammonium phosphate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41776189A | 1989-10-06 | 1989-10-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL95912A0 IL95912A0 (en) | 1991-07-18 |
| IL95912A true IL95912A (he) | 1998-08-16 |
Family
ID=23655307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9591290A IL95912A (he) | 1989-10-06 | 1990-10-07 | שיטה להארכת חיי מדף של תאי דם |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0494957B1 (he) |
| JP (1) | JP3069613B2 (he) |
| KR (1) | KR0185415B1 (he) |
| AT (1) | ATE176126T1 (he) |
| AU (1) | AU656718B2 (he) |
| DE (1) | DE69032923T2 (he) |
| ES (1) | ES2127188T3 (he) |
| FI (1) | FI107703B (he) |
| HU (1) | HU215185B (he) |
| IE (1) | IE903603A1 (he) |
| IL (1) | IL95912A (he) |
| WO (1) | WO1991004659A1 (he) |
| ZA (1) | ZA908043B (he) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0509083B1 (en) * | 1990-11-07 | 1997-07-16 | Baxter International Inc. | Red blood cell storage solution |
| EP1082006B1 (en) * | 1998-05-26 | 2006-02-01 | Lifecell Corporation | Cryopreservation of human red blood cells |
| US8828226B2 (en) | 2003-03-01 | 2014-09-09 | The Trustees Of Boston University | System for assessing the efficacy of stored red blood cells using microvascular networks |
| US9314014B2 (en) | 2004-02-18 | 2016-04-19 | University Of Maryland, Baltimore | Compositions and methods for the storage of red blood cells |
| CA2623666C (en) | 2005-09-26 | 2017-10-24 | Lifecell Corporation | Dry platelet composition |
| EP2211046B1 (en) | 2008-12-29 | 2011-03-02 | C.R.F. Società Consortile per Azioni | Fuel injection system with high repeatability and stability of operation for an internal-combustion engine |
| US10136635B2 (en) | 2010-05-05 | 2018-11-27 | New Health Sciences, Inc. | Irradiation of red blood cells and anaerobic storage |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| CN102905522A (zh) | 2009-10-12 | 2013-01-30 | 新健康科学股份有限公司 | 用于从红细胞中除去氧的氧消耗装置和方法 |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| NZ622456A (en) | 2009-10-12 | 2015-09-25 | New Health Sciences Inc | Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities |
| JP5930483B2 (ja) | 2010-08-25 | 2016-06-08 | ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． | 保存中の赤血球の品質及び生存を高める方法 |
| US10130751B2 (en) * | 2011-03-11 | 2018-11-20 | Fenwal, Inc. | Membrane separation and washing devices, systems and methods employing same, and data management systems and methods |
| EP2685815A4 (en) | 2011-03-16 | 2014-09-17 | Mayo Foundation | METHODS AND MATERIALS FOR EXTENDING USEFUL STORAGE OF PREPARATIONS OF HEMATIES AND PLATELET PREPARATIONS |
| US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
| PT4074395T (pt) | 2011-08-10 | 2024-05-20 | Hemanext Inc | Dispositivo de filtração integrado para depleção de leucócitos, oxigénio e/ou co2 e separação de plasma |
| JP5568103B2 (ja) * | 2012-02-20 | 2014-08-06 | ユニバーシティ・オブ・シンシナティ | 赤血球の保存のための組成物及び方法 |
| EP3967143A1 (en) | 2013-02-28 | 2022-03-16 | Hemanext Inc. | Gas addition device for blood treatment and corresponding method |
| JP6040307B2 (ja) * | 2013-04-01 | 2016-12-07 | テルモ株式会社 | 赤血球保存液、保存液収納容器、赤血球保存液の製造方法および血液バッグシステム |
| AU2016228993B2 (en) | 2015-03-10 | 2022-02-10 | Hemanext Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
| CA2983295C (en) | 2015-04-23 | 2024-02-13 | New Health Sciences, Inc. | Anaerobic blood storage containers |
| CN107735095B (zh) | 2015-05-18 | 2022-06-14 | 希玛奈克斯特股份有限公司 | 储存全血的方法及其组合物 |
| MX2018014530A (es) | 2016-05-27 | 2019-02-21 | New Health Sciences Inc | Almacenamiento anaerobico de sangre y metodo de inactivacion de patogenos. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD152719A1 (de) * | 1980-09-02 | 1981-12-09 | Klinke Birgit | Verfahren zur konservierung von erythrozyten |
| US4585735A (en) * | 1984-07-19 | 1986-04-29 | American National Red Cross | Prolonged storage of red blood cells |
| FR2581289A1 (fr) * | 1985-05-06 | 1986-11-07 | Rgl Transfusion Sanguine Centr | Solution synthetique pour la conservation prolongee de concentres erythrocytaires |
| JPS6363616A (ja) * | 1986-09-04 | 1988-03-22 | Showa Denko Kk | 赤血球濃厚液の保存剤及び保存方法 |
| DE3722984A1 (de) * | 1987-07-11 | 1989-01-19 | Biotest Pharma Gmbh | Waessrige loesung zum suspendieren und lagern von zellen, insbesondere erythrozyten |
-
1990
- 1990-10-07 IL IL9591290A patent/IL95912A/he not_active IP Right Cessation
- 1990-10-08 ZA ZA908043A patent/ZA908043B/xx unknown
- 1990-10-08 IE IE360390A patent/IE903603A1/en not_active IP Right Cessation
- 1990-10-09 AU AU66040/90A patent/AU656718B2/en not_active Ceased
- 1990-10-09 EP EP90915582A patent/EP0494957B1/en not_active Expired - Lifetime
- 1990-10-09 ES ES90915582T patent/ES2127188T3/es not_active Expired - Lifetime
- 1990-10-09 WO PCT/US1990/005817 patent/WO1991004659A1/en active IP Right Grant
- 1990-10-09 AT AT90915582T patent/ATE176126T1/de not_active IP Right Cessation
- 1990-10-09 JP JP2514579A patent/JP3069613B2/ja not_active Expired - Fee Related
- 1990-10-09 HU HU9201160A patent/HU215185B/hu unknown
- 1990-10-09 DE DE69032923T patent/DE69032923T2/de not_active Expired - Fee Related
-
1992
- 1992-04-03 FI FI921488A patent/FI107703B/fi active
- 1992-04-06 KR KR1019920700803A patent/KR0185415B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0494957B1 (en) | 1999-01-27 |
| ES2127188T3 (es) | 1999-04-16 |
| HU215185B (hu) | 1998-10-28 |
| FI107703B (fi) | 2001-09-28 |
| AU6604090A (en) | 1991-04-28 |
| HU9201160D0 (en) | 1992-08-28 |
| AU656718B2 (en) | 1995-02-16 |
| IE903603A1 (en) | 1991-04-10 |
| KR920702907A (ko) | 1992-12-17 |
| ATE176126T1 (de) | 1999-02-15 |
| JP3069613B2 (ja) | 2000-07-24 |
| HUT64440A (en) | 1994-01-28 |
| FI921488A (fi) | 1992-04-03 |
| DE69032923T2 (de) | 1999-08-19 |
| EP0494957A4 (en) | 1993-03-10 |
| WO1991004659A1 (en) | 1991-04-18 |
| DE69032923D1 (de) | 1999-03-11 |
| ZA908043B (en) | 1991-07-31 |
| EP0494957A1 (en) | 1992-07-22 |
| FI921488A0 (fi) | 1992-04-03 |
| KR0185415B1 (en) | 1999-04-01 |
| IL95912A0 (en) | 1991-07-18 |
| JPH05503075A (ja) | 1993-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2067134C (en) | Procedure for storing red cells with prolonged maintenance of cellular concentrations of atp and 2,3 dpg | |
| EP0494957B1 (en) | Procedure for storing red cells with prolonged maintenance of cellular concentrations of atp and 2,3 dpg | |
| USRE32874E (en) | Plasma-free medium for platelet storage | |
| AU705760B2 (en) | Long term storage of red cells in unfrozen solution | |
| AU710467B2 (en) | Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells | |
| EP0313808B1 (en) | Synthetic, plasma-free, transfusible storage medium for red blood cells | |
| US4675185A (en) | Solution for stabilizing red blood cells during storage | |
| US20150010897A1 (en) | Additive solution for blood preservation | |
| Meryman et al. | Prolonged storage of red cells at 4 C | |
| EP2420140A1 (en) | Compositions and methods for the storage of red blood cells | |
| JP2000516963A (ja) | 酸素除去・添加剤使用による赤血球長期保存法 | |
| EP0237863A1 (en) | Synthetic, plasma-free, transfusible platelet storage medium. | |
| NO167075B (no) | Suspensjonsmedium for forlenget lagring av roede blodceller | |
| EP1109447B1 (en) | Prolonged storage of red blood cells | |
| WO1996029864A1 (en) | Rejuvenating outdated red cells | |
| EP1244353B1 (en) | Compositions for the storage of platelets | |
| Åkerblom et al. | Studies on citrate‐phosphate‐dextrose (CPD) blood supplemented with adenine | |
| US20160081328A1 (en) | Solutions for Red Blood Cells | |
| Uda et al. | Preparation of blood components with saline‐adenine‐glucose‐phosphate‐maltose quadruple‐pack system | |
| US4838861A (en) | Blood preservation by ultrahemodilution | |
| Ross et al. | Additive solution for the suspension and storage of deglycerolized red blood cells | |
| JP2971475B2 (ja) | 赤血球及び血小板のための合成された、血漿を含まない輸血可能な貯蔵媒体 | |
| Meryman et al. | Extended storage of (washed) red cells at 4 C | |
| Meryman et al. | EXTENDED STORAGE OF (WASHED) RED CELLS AT | |
| Greenwalt et al. | Studies in red blood cell preservation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| FF | Patent granted | ||
| EXP | Patent expired |